First Time Loading...

Entera Bio Ltd
NASDAQ:ENTX

Watchlist Manager
Entera Bio Ltd Logo
Entera Bio Ltd
NASDAQ:ENTX
Watchlist
Price: 1.67 USD 8.44% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. [ Read More ]

The intrinsic value of one ENTX stock under the Base Case scenario is 0.16 USD. Compared to the current market price of 1.67 USD, Entera Bio Ltd is Overvalued by 91%.

Key Points:
ENTX Intrinsic Value
Base Case
0.16 USD
Overvaluation 91%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Entera Bio Ltd

Backtest ENTX Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ENTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Entera Bio Ltd

Current Assets 11.3m
Cash & Short-Term Investments 11m
Other Current Assets 238k
Non-Current Assets 508k
PP&E 488k
Other Non-Current Assets 20k
Current Liabilities 1.1m
Accounts Payable 83k
Accrued Liabilities 1m
Non-Current Liabilities 288k
Other Non-Current Liabilities 288k
Efficiency

Earnings Waterfall
Entera Bio Ltd

Revenue
0 USD
Operating Expenses
-8.9m USD
Operating Income
-8.9m USD
Other Expenses
2k USD
Net Income
-8.9m USD

Free Cash Flow Analysis
Entera Bio Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ENTX Profitability Score
Profitability Due Diligence

Entera Bio Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

19/100
Profitability
Score

Entera Bio Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

ENTX Solvency Score
Solvency Due Diligence

Entera Bio Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
49/100
Solvency
Score

Entera Bio Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ENTX Price Targets Summary
Entera Bio Ltd

Wall Street analysts forecast ENTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ENTX is 10.2 USD with a low forecast of 10.1 USD and a high forecast of 10.5 USD.

Lowest
Price Target
10.1 USD
505% Upside
Average
Price Target
10.2 USD
511% Upside
Highest
Price Target
10.5 USD
529% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ENTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ENTX Price
Entera Bio Ltd

1M 1M
+21%
6M 6M
+129%
1Y 1Y
+24%
3Y 3Y
-53%
5Y 5Y
-62%
10Y 10Y
-66%
Annual Price Range
1.67
52w Low
0.5507
52w High
1.72
Price Metrics
Average Annual Return -0.22%
Standard Deviation of Annual Returns 107.68%
Max Drawdown -93%
Shares Statistics
Market Capitalization 59.2m USD
Shares Outstanding 35 481 300
Percentage of Shares Shorted 0.08%

ENTX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Entera Bio Ltd Logo
Entera Bio Ltd

Country

Israel

Industry

Biotechnology

Market Cap

59.2m USD

Dividend Yield

0%

Description

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. The firm conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The firm develops drugs for hypoparathyroidism, osteoporosis and bone healing.

Contact

JERUSALEM
Hadassah / Jerusalem Bio, Park, 5th Floor
+97225327151.0
http://www.enterabio.com/

IPO

2018-06-28

Employees

18

Officers

CEO & Director
Ms. Miranda J. Toledano M.B.A.
Chief Operating Officer
Dr. Hillel Galitzer M.B.A., Ph.D.
Chief Financial Officer
Ms. Dana Yaacov-Garbeli CPA
Chief Medical Officer
Dr. Arthur C. Santora II, M.D., Ph.D.

See Also

Discover More
What is the Intrinsic Value of one ENTX stock?

The intrinsic value of one ENTX stock under the Base Case scenario is 0.16 USD.

Is ENTX stock undervalued or overvalued?

Compared to the current market price of 1.67 USD, Entera Bio Ltd is Overvalued by 91%.